MDM2 and non-small cell lung carcinoma: MDM2 was finally chosen for further evaluation not only because it ranked second in the cell cycle pathway but also because several small molecular inhibitors selectively targeting MDM2 are available to study the in vitro and in vivo efficacy against wtTP53‐RTK NSCLC.